Pediatric Dupixent trials

Disclaimer: Our office is not affiliated nor endorses any of these clinical trials. We are forwarding information about available clinical trials, it is the patient’s responsibility and due diligence to please review all risks and benefits with the clinical trial researchers prior to participating. 

DermAssociates, PC
Norman A. Lockshin, MD FAAD,FACP
Benjamin N. Lockshin, MD FAAD

Office:  10313 Georgia Avenue,  Suite 309
Silver Spring, Maryland 20902
 Clinical Trials: (301) 355-3183
15245 Shady Grove Road
 www.DermAssociates.com Suite 480 (south entrance)
 Rockville, Maryland 20850

Clinical Trials Center at DermAssociates is currently participating in a Phase 3
clinical research study for adolescent patients with moderate-to-severe atopic dermatitis. We are evaluating the efficacy of an investigational biologic agent called dupilumab which is a fully human monoclonal antibody directed
against IL-4 and IL-13. The results of studies looking at the efficacy and safety of dupilumab for moderate-to-severe
atopic dermatitis were recently published in Lancet 2016; 387: 40-52.
We are actively seeking patients ages ≥ 12-< 18 years of age with moderate-to-severe chronic atopic dermatitis to participate in this new phase 3 study. Eligible patients will be randomized in a 1:1:1 ratio to receive dupilumab or placebo for 12 weeks. The study is expected to demonstrate the efficacy and safety of dupilumab as
a monotherapy in adolescent patients. Patients who participate in the study may subsequently be eligible to participate in an open-label extension study.

 

 

Peanut OIT shows promise

Research results posted in Lancet are very promising.

Patient group ingesting peanut protein along with probiotics showed the majority of patients were able to tolerate peanuts vs placebo group.

Another step in the right direction to bringing such therapies to our patients soon.

Dupixent (Dupilimab) treatment for Atopic Dermatitis is now available

Dupixent, humanized monoclonal antibody, anti-IL-4, anti-IL13, is now available for the treatment of poorly controlled moderate to severe Atopic dermatitis/eczema in patients ages 18 years and older. Studies are under way for patients under 18 years of age.

It is a small injection under the skin every 2 week.

Contact our office for an appointment if you are interested in finally getting her eczema under control.

Albuterol Ventolin RECALL

Recall of Ventolin (Albuterol) by GSK. If your Albuterol is name brand Ventolin then please check to make sure it is not recalled. The affected lot numbers are 6ZP0003, 6ZP9944 and 6ZP9848. Contact GSK’s customer service center at 1-888-825-5249 with questions.

http://www.cnn.com/2017/04/06/health/albuterol-inhaler-recall/

Treatment for Chronic Hives

Xolair is approved down to the age of 12 years old for the treatment of Chronic Idiopathic Urticaria (Chronic Hives).  So if taking antihistamines is not providing complete relief or the side effects of antihistamines is too much to handle then this may the relief you are looking for. It’s a once a month injection under your skin (on the back of your arms). It’s a unique treatment given by your allergist.

Prevent peanut allergy

For infants under the age of 12months, if they are at high risk (+family history of peanut allergy; eczema, allergies), we are offering early introduction protocol in order to prevent them from developing a peanut allergy.

Based on the LEAP Study, regular feeding of peanut protein to children at high risk can significantly reduce the development of peanut allergy.

Make an appt for your at risk infant to be evaluated for a peanut allergy, prior to starting the introduction.

Auvi Q is now available

For our patients who liked the Auvi Q, it is set to return to the market February 14, 2017 and will be free to most patients with commercial insurance.

Call our office to request a prescription. If you have not been seen in the past 12 months then schedule an appointment asap.